BioNTech SE (BioNTech SE) Additional Paid-In Capital : $1,341 Mil(As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Additional Paid-In Capital?

BioNTech SE's quarterly additional paid-in capital declined from Jun. 2023 ($1,543 Mil) to Sep. 2023 ($1,311 Mil) but then increased from Sep. 2023 ($1,311 Mil) to Dec. 2023 ($1,341 Mil).

BioNTech SE's annual additional paid-in capital increased from Dec. 2021 ($1,892 Mil) to Dec. 2022 ($1,937 Mil) but then declined from Dec. 2022 ($1,937 Mil) to Dec. 2023 ($1,341 Mil).

BioNTech SE Additional Paid-In Capital Historical Data

The historical data trend for BioNTech SE's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Additional Paid-In Capital Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

763.02

1,842.46

1,891.98

1,936.65

1,340.68

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,936.65	1,657.28	1,543.23	1,310.99	1,340.68

BioNTech SE Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

BioNTech SE Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.